FindTrial
Sign In

Jardiance 25 mg film-coated tablets

DRUG6 trials

Sponsors

Steno Diabetes Center Copenhagen, Universitaetsspital Basel, Karolinska University Hospital, Odense University Hospital, Center For Outcomes Research And Clinical Epidemiology S.r.l.

Conditions

Diabetes type 2HyponatremiaKidney transplant recipientsMaturity-onset diabetes of the young type 3 (HNF1A-MODY)Myocardial InfarctionType 2 diabetes mellitusdiabetes mellitus

Phase 2

Effects of empagliflozin on plasma glucose in patients with HNF1A-MODY: a randomized, double-blind, crossover trial
CompletedCTIS2023-503760-17-00
Steno Diabetes Center CopenhagenMaturity-onset diabetes of the young type 3 (HNF1A-MODY)
Start: 2023-10-11End: 2024-11-29Target: 24Updated: 2024-07-31
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone and Semaglutide (DiaSpax)
RecruitingCTIS2024-513416-98-00
Karolinska University HospitalDiabetes type 2
Start: 2023-01-23Target: 90Updated: 2025-11-25
Acute effects of SGLT2 inhibitor on kidney allograft oxygen tension: A randomized, double-blind, placebo controlled crossover trial
CompletedCTIS2024-513765-40-00
Odense University HospitalKidney transplant recipients
Start: 2025-03-27End: 2025-09-09Target: 8Updated: 2025-01-21
Effect of the SGLT2 inhibitor empagliflozin in patients with euvolemic and hypervolemic hyponatremia – a multicentric randomized double-blind placebo-controlled trial (the EMPOWER Study)
RecruitingCTIS2023-508610-42-00
Universitaetsspital BaselHyponatremia
Start: 2025-10-17Target: 60Updated: 2025-09-03

Phase 3

Sodium-glucose cotransporter-2 inhibitors to stABiLizE coronary atherosclerosis pro-gression after acute Myocardial Infarction in women and men with diabetes mellitus
Not yet recruitingCTIS2025-523375-29-00
Humanitas Mirasole S.p.A.diabetes mellitus, Myocardial Infarction
Target: 300Updated: 2026-02-06

Phase 4

Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial.
CompletedCTIS2024-518915-20-00
Center For Outcomes Research And Clinical Epidemiology S.r.l.Type 2 diabetes mellitus
Start: 2022-02-16End: 2025-10-02Target: 1167Updated: 2025-09-30